Dopamine D2 receptor Inhibitors
2 drugsAbout Dopamine D2 receptor
The Dopamine D2 receptor (D2R) is a G protein-coupled receptor crucial for motor control, reward pathways, and hormone regulation within the central nervous system. As a key member of the dopamine receptor family, it plays a significant role in various physiological processes.
Despite the absence of direct genetic evidence linking D2R to specific diseases, its established role in dopamine signaling makes it a compelling therapeutic target. This suggests potential for developing novel therapies in areas such as metabolic disorders and other conditions where dopamine signaling plays a role.
Two approved drugs, MODEYSO and CYCLOSET, target D2R, highlighting its clinical relevance. These drugs, developed by CHIMERIX and VEROSCIENCE, are small molecules and are indicated for metabolic conditions and other therapeutic areas.
Top Dopamine D2 receptor Drugs
CHIMERIX and VEROSCIENCE are the only two companies with approved drugs targeting the D2 receptor.
Low market concentration suggests an opportunity for new entrants, but may also indicate high entry barriers.
Dopamine D2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Dopamine D2 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Dopamine D2 receptor Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Dopamine D2 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 1 | 1 | 1 | 50% |
| Phase 2 | 7 | 4 | 3 | 0 | 57% |
| Phase 3 | 4 | 0 | 1 | 3 | 0% |
| Phase 4 | 6 | 3 | 1 | 2 | 75% |
Top Sponsors
By Modality
Dopamine D2 receptor Drug Approval Timeline (2009 - 2025)
The first drug was approved in 2009, with the most recent approval in 2025, spanning 17 years.
The recent approval suggests renewed interest in the target, but further approvals are needed to confirm a trend.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 16 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Dopamine D2 receptor. A trial counts if an approved drug acting on Dopamine D2 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.